June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

June 23, 2025

Slower Steps May Signal Worsening COPD

A large European study found that people with COPD walk slower and have reduced gait performance compared to healthy adults, with impairments worsening as disease severity increases.

Conexiant

June 23, 2025

Remote and Ready: Rethinking COPD Care

A large meta-analysis of 33 trials found that community-based COPD management models improved lung function, exercise capacity, and symptom control compared to usual care, though quality-of-life gains were not significant.

Conexiant

June 13, 2025

RSV Vaccine Approved for Younger Adults

The FDA has approved Moderna’s mRESVIA vaccine for adults aged 18 to 59 who are at increased risk for RSV, expanding its indication beyond older adults.

Conexiant

June 06, 2025

FDA Monthly Round-up: Key May Updates

May’s FDA approvals include the first at-home HPV test, a blood-based Alzheimer’s diagnostic, biosimilars, AI-enabled imaging tools, and novel therapies across cardiology, pulmonology, neurology, gastroenterology, and more.

Conexiant

June 04, 2025

Big Tobacco's Medical Research Infiltrates Journals

Investigation reveals tobacco-funded studies appear in top medical journals despite industry bans, as companies invest billions in pharmaceutical subsidiaries.

Conexiant

June 02, 2025

New COVID Vaccine Approved for High-Risk Groups

After showing higher efficacy and a comparable safety profile to Spikevax, the FDA has approved Moderna’s mNEXSPIKE COVID-19 vaccine for high-risk patients.

Conexiant

December 13, 2024

New Vaccine Prevents Severe RSV Illness

A recent study showed the new vaccine was more than 90% effective in the prevention of hospitalizations and emergency department visits due to RSV among those 60 years old or older.

Conexiant

November 13, 2024

Is COPD Set to Affect 600M Globally?

GOLD 2025 highlights new pathways and advanced COPD therapies like ensifentrine and dupilumab to reduce exacerbations and address emerging COPD phenotypes.

Conexiant